Results: 1-25 | 26-50 | 51-75 | 76-100 | >>

Table of contents of journal: *Cancer chemotherapy and pharmacology

Results: 76-100/1592

Authors: Wang, ZY
Citation: Zy. Wang, Arsenic compounds as anticancer agents, CANC CHEMOT, 48, 2001, pp. S72-S76

Authors: Mauro, MJ O'Dwyer, ME Druker, BJ
Citation: Mj. Mauro et al., ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy, CANC CHEMOT, 48, 2001, pp. S77-S78

Authors: Slavin, S Or, R Aker, M Shapira, MY Panigrahi, S Symeonidis, A Cividalli, G Nagler, A
Citation: S. Slavin et al., Nonmyeloablative stem cell transplantation for the treatment of cancer andlife-threatening nonmalignant disorders: past accomplishments and future goals, CANC CHEMOT, 48, 2001, pp. S79-S84

Authors: Tobinai, K
Citation: K. Tobinai, Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan, CANC CHEMOT, 48, 2001, pp. S85-S90

Authors: Witzig, TE
Citation: Te. Witzig, Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma, CANC CHEMOT, 48, 2001, pp. S91-S95

Authors: Miyagishi, M Kuwabara, T Taira, K
Citation: M. Miyagishi et al., Transport of intracellularly active ribozymes to the cytoplasm, CANC CHEMOT, 48, 2001, pp. S96-S101

Authors: Saijo, N Tamura, T Yamamoto, N Nishio, K
Citation: N. Saijo et al., New strategies for cancer therapy in the 21st century, CANC CHEMOT, 48, 2001, pp. S102-S106

Authors: Zanker, KS
Citation: Ks. Zanker, The use of systemic enzyme therapy in oncology, CANC CHEMOT, 47, 2001, pp. S1-S3

Authors: Lauer, D Muller, R Cott, C Otto, A Naumann, M Birkenmeier, G
Citation: D. Lauer et al., Modulation of growth factor binding properties of alpha 2-macroglobulin byenzyme therapy, CANC CHEMOT, 47, 2001, pp. S4-S9

Authors: Desser, L Holomanova, D Zavadova, E Pavelka, K Mohr, T Herbacek, I
Citation: L. Desser et al., Oral therapy with proteolytic enzymes decreases excessive TGF-beta levels in human blood, CANC CHEMOT, 47, 2001, pp. S10-S15

Authors: Wald, M Olejar, T Sebkova, V Zadinova, M Boubelik, M Pouckova, P
Citation: M. Wald et al., Mixture of trypsin, chymotrypsin and papain reduces formation of metastases and extends survival time of C(57)Bl(6) mice with syngeneic melanoma B16, CANC CHEMOT, 47, 2001, pp. S16-S22

Authors: Gujral, MS Patnaik, PM Kaul, R Parikh, HK Conradt, C Tamhankar, CP Daftary, GV
Citation: Ms. Gujral et al., Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers, CANC CHEMOT, 47, 2001, pp. S23-S28

Authors: Dale, PS Tamhankar, CP George, D Daftary, GV
Citation: Ps. Dale et al., Co-medication with hydrolytic enzymes in radiation therapy of uterine cervix: evidence of the reduction of acute side effects, CANC CHEMOT, 47, 2001, pp. S29-S34

Authors: Schneider, B
Citation: B. Schneider, Analysis of therapeutic efficacy in observational cohort studies, CANC CHEMOT, 47, 2001, pp. S35-S37

Authors: Sakalova, A Bock, PR Dedik, L Hanisch, J Schiess, W Gazova, S Chabronova, I Holomanova, D Mistrik, M Hrubisko, M
Citation: A. Sakalova et al., Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma, CANC CHEMOT, 47, 2001, pp. S38-S44

Authors: Beuth, J Ost, B Pakdaman, A Rethfeldt, E Bock, PR Hanisch, J Schneider, B
Citation: J. Beuth et al., Impact of complementary oral enzyme application on the postoperative treatment results of breast cancer patients - results of an epidemiological multicentre retrolective cohort study, CANC CHEMOT, 47, 2001, pp. S45-S54

Authors: Popiela, T Kulig, J Hanisch, J Bock, PR
Citation: T. Popiela et al., Influence of a complementary treatment with oral enzymes on patients with colorectal cancers - an epidemiological retrolective cohort study, CANC CHEMOT, 47, 2001, pp. S55-S63

Authors: Amtmann, E Zoller, M Wesch, H Schilling, G
Citation: E. Amtmann et al., Antitumoral activity of a sulphur-containing platinum complex with an acidic pH optimum, CANC CHEMOT, 47(6), 2001, pp. 461-466

Authors: van de Poll, MEC Relling, MV Schuetz, EG Harrison, PL Hughes, W Flynn, PM
Citation: Mec. Van De Poll et al., The effect of atovaquone on etoposide pharmacokinetics in children with acute lymphoblastic leukemia, CANC CHEMOT, 47(6), 2001, pp. 467-472

Authors: Ling, YH Donato, NJ Perez-Soler, R
Citation: Yh. Ling et al., Sensitivity to topoisomerase I inhibitors and cisplatin is associated withepidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines, CANC CHEMOT, 47(6), 2001, pp. 473-480

Authors: Du, YH Ho, PC
Citation: Yh. Du et Pc. Ho, Arsenic compounds induce cytotoxicity and apoptosis in cisplatin-sensitiveand -resistant gynecological cancer cell lines, CANC CHEMOT, 47(6), 2001, pp. 481-490

Authors: Zhao, LL Kestell, P Philpott, M Ching, LM Zhuang, L Baguley, BC
Citation: Ll. Zhao et al., Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), CANC CHEMOT, 47(6), 2001, pp. 491-497

Authors: Riccardi, A Meco, D Ferlini, C Servidei, T Carelli, G Segni, G Manzotti, C Riccardi, R
Citation: A. Riccardi et al., In vitro and in vivo antitumor activity of the novel trinuclear platinum complex BBR 3464 in neuroblastoma, CANC CHEMOT, 47(6), 2001, pp. 498-504

Authors: Sofowora, GG Choo, EF Mayo, G Shyr, Y Wilkinson, GR
Citation: Gg. Sofowora et al., In vivo inhibition of human CYP1A2 activity by oltipraz, CANC CHEMOT, 47(6), 2001, pp. 505-510

Authors: Kim, SG Sung, M Kang, KW Kim, SH Son, MH Kim, WB
Citation: Sg. Kim et al., DA-125, a novel anthracycline derivative showing high-affinity DNA bindingand topoisomerase II inhibitory activities, exerts cytotoxicity via c-Jun N-terminal kinase pathway, CANC CHEMOT, 47(6), 2001, pp. 511-518
Risultati: 1-25 | 26-50 | 51-75 | 76-100 | >>